Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Aldehyde dehydrogenase 2 and PARP1 interaction modulates hepatic HDL biogenesis by LXRα-mediated ABCA1 expression
Luxiao Li, Shanshan Zhong, Rui Li, Ningning Liang, Lili Zhang, Shen Xia, Xiaodong Xu, Xin Chen, Shiting Chen, Yongzhen Tao, Huiyong Yin
Luxiao Li, Shanshan Zhong, Rui Li, Ningning Liang, Lili Zhang, Shen Xia, Xiaodong Xu, Xin Chen, Shiting Chen, Yongzhen Tao, Huiyong Yin
View: Text | PDF
Research Article Cell biology Metabolism

Aldehyde dehydrogenase 2 and PARP1 interaction modulates hepatic HDL biogenesis by LXRα-mediated ABCA1 expression

  • Text
  • PDF
Abstract

HDL cholesterol (HDL-C) predicts risk of cardiovascular disease (CVD), but the factors regulating HDL are incompletely understood. Emerging data link CVD risk to decreased HDL-C in 8% of the world population and 40% of East Asians who carry an SNP of aldehyde dehydrogenase 2 (ALDH2) rs671, responsible for alcohol flushing syndrome; however, the underlying mechanisms remain unknown. We found significantly decreased HDL-C with increased hepatosteatosis in ALDH2-KO (AKO), ALDH2/LDLR–double KO (ALKO), and ALDH2 rs671–knock-in (KI) mice after consumption of a Western diet. Metabolomics identified ADP-ribose as the most significantly increased metabolites in the ALKO mouse liver. Moreover, ALDH2 interacted with poly(ADP-ribose) polymerase 1 (PARP1) and attenuated PARP1 nuclear translocation to downregulate poly(ADP-ribosyl)ation of liver X receptor α (LXRα), leading to an upregulation of ATP-binding cassette transporter A1 (ABCA1) and HDL biogenesis. Conversely, AKO or ALKO mice exhibited lower HDL-C with ABCA1 downregulation due to increased nuclear PARP1 and upregulation of LXRα poly(ADP-ribosyl)ation. Consistently, PARP1 inhibition rescued ALDH2 deficiency–induced fatty liver and elevated HDL-C in AKO mice. Interestingly, KI mouse or human liver tissues showed ABCA1 downregulation with increased nuclear PARP1 and LXRα poly(ADP-ribosyl)ation. Our study uncovered a key role of ALDH2 in HDL biogenesis through the LXRα/PARP1/ABCA1 axis, highlighting a potential therapeutic strategy in CVD.

Authors

Luxiao Li, Shanshan Zhong, Rui Li, Ningning Liang, Lili Zhang, Shen Xia, Xiaodong Xu, Xin Chen, Shiting Chen, Yongzhen Tao, Huiyong Yin

×

Figure 2

ALDH2 deficiency and Western diet feeding decreases hepatic ABCA1 expression without significantly affecting LXRα.

Options: View larger image (or click on image) Download as PowerPoint
ALDH2 deficiency and Western diet feeding decreases hepatic ABCA1 expres...
(A) Hepatic mRNA levels of ABCA1 and ALDH2 in WT and AKO mouse tissues at 32nd week (Western diet for 26 weeks). WT, n = 5; AKO, n = 5. (Β) Western blotting analysis of ABCA1 and LXRα expressions in WT and AKO liver tissue. WT, n = 3; AKO, n = 3. (C) Hepatic mRNA levels of LXRα and ABCA1 in LKO and ALKO mice at 32nd week (Western diet for 26 weeks). LKO, n = 5; ALKO, n = 5. (D) Western blotting analysis of ABCA1 and LXRα expression in LKO and ALKO liver tissues. LKO, n = 3; ALKO, n = 3. (E) Western blotting analysis of ABCA1; LXRα expression in LKO and ALKO hepatocytes treated with ox-LDL (50 μg/mL, 16 h). LKO, n = 3; ALKO, n = 3. (F) Western blotting analysis of ABCA1 expression in overexpressed ALDH2 (over-AL) hepatocytes treated with ox-LDL (50 μg/mL, 16 h). LKO, n = 3; ALKO, n = 3. (G) IHC analysis of ABCA1 expressions in mouse liver sections (LKO, n = 5; ALKO, n = 5; scale bar: 100 μm). Statistical comparisons were made using a 2-tailed Student’s t test. All data are mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts